-+ 0.00%
-+ 0.00%
-+ 0.00%

Thryv Therapeutics raises $30 million in Series B led by InClin

PUBT·11/04/2026 18:53:04
Thryv Therapeutics raises $30 million in Series B led by InClin
  • Thryv Therapeutics raised $30 million in Series B financing led by InClin, with support from existing investors including Lumira Ventures.
  • The clinical-stage biotechnology company develops precision therapies for inherited channel disorders, cardiometabolic diseases and cardiomyopathies.
  • Proceeds will fund the Phase 2a ASPIRE-HF trial of THRV-1268 in heart failure through a prespecified safety and efficacy analysis.
  • ASPIRE-HF will open enrollment in early 2027 for adults with symptomatic heart failure with reduced ejection fraction and QTc prolongation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lumira Capital Investment Management Inc published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.